GeneTex
  • Country / Location Selection

United States (US)

DR6 peptide

Cat No. GTX28450

Application Blocking
Species Human
Package
50 μg ($179)
APPLICATION

Application Note

The peptide is used for blocking the activity of DR6 (GTX28417). Incubatingthe peptide with equal volume of antibody for 30 min at 37ºC usually completely blocks theantibody activity in Western blotting.
PROPERTIES

Form

Liquid

Buffer

PBS pH7.2 with 10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl, 0.1% bovine serum albumin, and 0.02% sodium azide

Storage

Store the peptide at -20˚C, stable for one year.

Concentration

0.20 mg/ml (Please refer to the vial label for the specific concentration.)

Conjugation

Unconjugated

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

Tnf Receptor Superfamily Member 21,Bm-018,Cd358,Dr6,Tnfrsf21

Background

Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain containing receptors, TNFR1 and Fas. Several novel death receptors including DR3, DR4, and DR5 were recently identified. A new death domain containing receptor in the TNFR family was cloned recently and termed DR6 for death receptor 6. Like TNFR1, DR6 interacts with death domain containing adapter molecule TRADD. Overexpression of DR6 induces apoptosis and activates NF-kB and JNK. DR6 is widely expressed inhuman tissues and cell lines. The ligand for DR6 hasnot been identified.
REFERENCE
There are currently no references for DR6 peptide (GTX28450). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for DR6 peptide (GTX28450). Be the first to share your experience with this product.
Package List Price ($)
$ 179